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Abstract
Background: Arginine metabolism in tumor cell lines can be influenced by various cytokines,
including recombinant human interferon-γ (rIFN-γ), a cytokine that shows promising clinical activity
in epithelial ovarian cancer (EOC).
Methods: We examined EOC cell lines for the expression of arginase in an enzymatic assay and
for transcripts of arginase I and II, inducible nitric oxide synthase (iNOS), and indoleamine 2,3-
dioxygenase (IDO) by reverse transcription-polymerase chain reaction. The effects of rIFN-γ on
arginase activity and on tumor cell growth inhibition were determined by measuring [3H]thymidine
uptake.
Results: Elevated arginase activity was detected in 5 of 8 tumor cell lines, and analysis at the
transcriptional level showed that arginase II was involved but arginase I was not. rIFN-γ reduced
arginase activity in 3 EOC cell lines but increased activity in the 2008 cell line and its platinum-
resistant subline, 2008.C13. iNOS transcripts were not detected in rIFN-γ-treated or untreated
cell lines. In contrast, IDO activity was induced or increased by rIFN-γ. Suppression of arginase
activity by rIFN-γ in certain cell lines suggested that such inhibition might contribute to its
antiproliferative effects. However, supplementation of the medium with polyamine pathway
products did not interfere with the growth-inhibitory effects of rIFN-γ EOC cells.
Conclusions: Increased arginase activity, specifically identified with arginase II, is present in most
of the tested EOC cell lines. rIFN-γ inhibits or stimulates arginase activity in certain EOC cell lines,
though the decrease in arginase activity does not appear to be associated with the in vitro
antiproliferative activity of rIFN-γ. Since cells within the stroma of EOC tissues could also
contribute to arginine metabolism following treatment with rIFN-γ or rIFN-γ-inducers, it would be
helpful to examine these effects in vivo.
Published: 19 September 2003
Journal of Translational Medicine 2003, 1:5
Received: 28 August 2003
Accepted: 19 September 2003
This article is available from: http://www.translational-medicine.com/content/1/1/5
© 2003 Melichar et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/5
Page 2 of 9
(page number not for citation purposes)
Background
Arginine metabolism to nitric oxide (NO) via nitric oxide
synthase or to ornithine via arginase is an important bio-
logical pathway (see Fig. 1). NO has many important
functions, including regulating vascular tone and facilitat-
ing cell-mediated cytotoxicity [1], and ornithine is the
immediate precursor of polyamines, which are important
in cell proliferation [2]. In addition to competition for the
substrate, L-arginine, there are other interactions between
the two pathways of arginine metabolism, such as the
inhibition of arginase by NG-hydroxy-L-arginine, an inter-
mediate in NO biosynthesis [3,4].
Under different experimental conditions, NO may either
inhibit [5,6] or promote [7] tumor growth. On the other
hand, polyamines appear to be necessary for the prolifer-
ation of neoplastic cells, and polyamine depletion results
in tumor growth arrest [8]. Inducible nitric oxide synthase
(iNOS) catalyzes the production of NO, which contrib-
utes to the antitumor activity of activated macrophages
[9]. iNOS expression is induced by cytokines, primarily
the pro-inflammatory cytokine rIFN-α [9] which may be
produced by certain T-lymphocytes and natural killer
(NK) cells that are important in adaptive and innate
immune responses, respectively [12]. iNOS and arginase
are differentially regulated by pro- and anti-inflammatory
cytokines [10,11]. In addition, rIFN-γ(rIFN) can have a
direct antiproliferative effect on tumor cell lines in vitro,
including a number of ovarian cancer cell lines [13–15].
This antiproliferative activity in some experimental sys-
tems depends on the catabolism of another amino acid, L-
tryptophan, by indoleamine 2,3-dioxygenase (IDO)
[13,14,16,17]. The antitumor activity of rIFN-γ, adminis-
tered either intraperitoneally [18] or systemically [19], has
also been observed in clinical trials involving epithelial
ovarian carcinoma (EOC).
Arginine pathway Figure 1
Arginine pathway. L-arginine is metabolized either by nitric oxide synthase to N-hydroxy-L-arginine and NO, or by arginase 
to ornithine and urea. IFN-γ induces nitric oxide synthase, but inhibits arginase. N-hydroxy-L-arginine inhibits arginase, and NO 
inhibits ornithine decarboxylase.
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In this study, we examined L-arginine metabolism in EOC
cell lines and the effect of rIFN-γ on arginase activity. Argi-
nase expression varied among EOC cell lines. In some cell
lines, rIFN-γ reduced arginase activity and expression;
however, no direct relationship between arginase activity
and the growth inhibitory effects of rIFN-γ was observed.
Methods
Reagents
rIFN-γ (Actimmune) was obtained from Intermune Phar-
maceuticals (Burlingame, CA). L-NG-monomethyl
arginine citrate (NMMA) was obtained from Cayman
Chemical Company (Ann Arbor, MI) NG-hydroxy-L-
arginine was obtained from Alexis (Carlsbad, CA). Orni-
thine, putrescine, and spermidine were obtained from
Sigma (St. Louis, MO).
Cell lines
The 2774 cell line was originally isolated from an ovarian
cancer patient in the laboratory of Dr. J. Sinkovics as pre-
viously described [20]. The NMP-1 cell line is a moder-
ately platinum-resistant tumor cell line developed from
the parental OVCAR3 line by in vitro incubation of the
cell with increasing cisplatin concentrations and subse-
quent passage in the nude mouse in the laboratory of Dr.
Jim Klostergaard at The University of Texas M. D. Ander-
son Cancer Center [21]. The HEY line was originally
derived from a human ovarian cancer xenograft, and is
characterized by moderate resistance to cisplatin [22].
Both the HEY and NMP-1 cell lines were obtained from
Dr. Klostergaard. The 2008 cell line and its platinum-
resistant subline, 2008.C13 [23], were obtained from Dr.
Zahid Siddik, M. D. Anderson Cancer Center. CAOV3and
SKOV3, which overexpress HER2/neu, were obtained
from American Type Culture Collection (Manassas, VA).
All cell lines were grown in RPMI 1640 (GIBCO, Grand
Island, NY) supplemented with 10% fetal calf serum
(Sigma) at 37°C in 5% CO2. 2774 and 2008 are sensitive
to platinum. The remaining lines exhibit varying degrees
of resistance to platinum.
Measurement of arginase activity
Arginase activity was measured as previously described
[24]. Briefly, 5 × 105 cells were obtained by trypsinization
and washed twice with phosphate-buffered saline (PBS,
GIBCO). To each sample, 50 ml of 0.1% Triton X-100
(Curtin-Matheson, Houston, TX) containing 5 µg pepsta-
tin, 5 µg aprotinin, and 5 µg of antipain (Sigma) were
added, and the samples were shaken for 1 hour at room
temperature. An aliquot was then taken for the determina-
tion of protein content, 50 µl of 10 mM manganese chlo-
ride (Sigma) in 50 mM Tris-HCl (Fisher, Fair Lawn, NJ),
pH 7.5, were then added to the sample and the samples
were incubated for 10 minutes at 55°C. Afterwards, 25 µl
of the sample was transferred to Eppendorf tubes, 25 µl of
0.5 M arginine (Sigma), pH 9.7, was added, and the mix-
ture was incubated at 37°C. After 1 hour, the reaction was
stopped by 400 µl of acid mixture (sulfuric acid, phos-
phoric acid, and water 1:3:7), 25 µl of 9% α-isonitroso-
propiophenone in ethanol (Sigma), was added and the
samples were heated at 100°C for 1 hour. After 10 min-
utes in the dark, optic density at 540 nm was determined
using a microplate reader. A calibration curve was pre-
pared using increasing concentrations of urea (Curtin-
Matheson). In certain experiments, NMMA, an iNOS
inhibitor, was added to study a possible role of iNOS
induction in the suppression of arginase activity by rIFN-γ.
The protein content of each sample was measured using a
bicinchoninic acid method with a commercial kit (Pierce,
Rockford, IL) according the manufacturer's instructions.
The arginase activity was then expressed as µg of urea per
mg of protein.
Immunocytochemistry
The expression of Ki-67, a marker of proliferation, on cul-
tured EOC cell lines was evaluated by immunocytochem-
istry [25]. Briefly, cytospin preparations of cultured EOC
cell lines were fixed with acetone at room temperature and
air-dried. After blocking with 0.3% hydrogen peroxide in
methanol, the slides were washed twice with PBS and
blocked with 1% horse serum. The slides were then incu-
bated with Ki-67 mouse anti-human monoclonal anti-
body (Pharmingen, San Diego, CA) for 1 hour. The slides
were washed twice with PBS and then incubated with a
biotin-conjugated secondary antibody for 1 hour at room
temperature. After two washes with PBS, the slides were
stained using an avidin-biotin-peroxidase complex stain-
ing kit (Vector Laboratories, Burlingame, CA) following
the manufacturer's instructions. After counterstaining
with hematoxylin QS H-3404 (Vector), the proportion of
positively stained cells was measured.
RNA extraction
The RNA extraction was performed using TRIzol (Invitro-
gen Life Technologies, Carlsbad, CA). The procedure was
performed according the manufacturer's instructions.
Reverse transcription-polymerase chain reaction
The expression of iNOS, arginase I, and arginase II in ovar-
ian cancer cells treated with and without IFN-γ was exam-
ined using a reverse transcription-polymerase chain
reaction (RT-PCR).
Reverse transcription was performed using 1–5 µg of total
RNA diluted in 11.5 µl of diethylpyrocarbamate-treated
water. One microliter of random primers (GIBCO) were
added to each RNA sample in a sterile PCR tube. The mix-
ture was then heated at 70°C for 10 minutes. Immediately
afterward, the samples were chilled on ice, and 4 µl ofJournal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/5
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first-strand buffer (GIBCO), 2 µl of 0.1 M DTT (GIBCO),
1 µl of RNse inhibitor (Roche, Mannheim, Germany) and
0.5 µl of 25 mM dNTP (GIBCO) were added to each sam-
ple. The samples were then incubated for 10 minutes at
25°C and 2 minutes at 42°C. One microliter of reverse
transcriptase (Superscript II, GIBCO) was then added, and
the reaction was continued at 42°C for another 45 min-
utes. The reaction was then stopped by heating the tubes
at 95°C for 5 minutes, and the complementary DNA
(cDNA) obtained was stored at -20°C until needed for
further analysis.
The cDNA samples were then amplified using a polymer-
ase chain reaction [26]. The following primers were used
(GIBCO):
iNOS sense 5'-CATGGCTTGCCCCTGGAAGTTTCT-3',
antisense 5'-CCTCTATGGTGCCATCGGGCATC-3';
arginase I sense 5'-CTCTAAGGGACAGCCTCGAGGA-3',
antisense 5'-TGGGTTCACTTCCATGATATCTA-3';
arginase II sense 5'-ATGTCCCTAAGGGGCAGCCTCTCG-
CGT-3',
antisense 5'-CACAGCTGTAGCCATCTGACACAGCTC-3';
IDO sense 5'-CCTGACTTATGAGAACATGGACGT-3',
antisense 5'-ATACACCAGACCGTCTGATAGCTG-3';
β-actin sense, 5'-GTTGCTATCCAGGCTGTGC-3',
and antisense, 5'-GCATCCTGTCGGCAATGC-3'.
The amplification was performed in 25 µl of reaction mix-
ture containing primers, 1 µl dimethyl sulfoxide (Sigma),
PCR buffer, 0.2 mM dNTP, 1.5 mM magnesium chloride,
and 5 U Taq DNA polymerase (GIBCO) under amplifica-
tion conditions described previously [27,28]. The final
PCR product was loaded on a 1.5 % agarose gel, separated
by electrophoresis, and visualized using ethidium bro-
mide staining under ultraviolet light. The expected sizes of
the amplified fragments were: iNOS, 747 base pairs (bp);
arginase I, 794 bp; arginase II, 342 bp; IDO,321 bp;
GAPDH, 558 bp; and β-actin, 567 bp. The semi-quantita-
tive measurement of transcript expression was analyzed
using a Scion image tool. The relative arbitrary units of
transcript expression were normalized using the value of
β-actin. GAPDH was used to control the quality of cDNA
in certain experiments.
Measurement of growth inhibition
The growth inhibitory activity of rIFN-γ was examined by
inhibition of [3H]thymidine incorporation [29]. Briefly,
5000 cells were seeded into flat-bottom 96-well plates
(Becton Dickinson, Franklin Lakes, NJ) and incubated
with the agent of interest in RPMI 1640 supplemented
with 10% fetal calf serum for 72 hours. For the last 16
hours, the cells were pulsed with 50 µl of [3H]thymidine
(10 µCi/ml, specific activity 185 Bq/mmol, Amersham,
Piscataway, NJ). The cytostasis experiment was then har-
vested. The cells were washed 3 times with phosphate-
buffered saline (GIBCO), and subsequently lysed with
150 µl of 0.1 M sodium hydroxide (Curtin Matheson).
The lysate was subsequently transferred to 3 ml scintilla-
tion liquid (Safety-Solve, Research Products International,
Mount Prospect, IL), and radioactivity was determined
using a WinSpectral liquid scintillation counter (EF&G
Wallac, Turku, Finland). The percentage of cytostasis for
each treatment was calculated using the formula:
(cpmcontrol cells - cpmtreated cells) × 100/cpmcontrol cells.
In certain experiments, the polyamines (ornithine,
putrescine and spermidine) were added to study the effect
of polyamines on rIFN-γ-induced cytostasis. NG-hydroxy-
L-arginine, an arginase inhibitor, was added to study the
effect of arginase suppression on the proliferation of EOC
cell lines.
Results and Discussion
Arginase activity varied among EOC cell lines. There was
no apparent relationship between the expression of argin-
ase activity in EOC tumor cell lines and the expression of
the Ki-67 antigen. Arginase activity was lower (less than
0.2 µg urea per mg protein) in 3 EOC cell lines – HEY,
SKOV3, and OVCAR3 and higher in 2774, CAOV3, NMP-
1, and 2008, and in its platinum-resistant subline,
2008.C13 (Table 1). Arginase activity was also higher in
the NMP-1 cell line, the cisplatin-resistant subline of
OVCAR3. Arginase activity decreased markedly after treat-
ment of 2774, NMP-1, and CAOV3 cells with rIFN-γ. In
contrast, rIFN-γ treatment leads to an increase of arginase
activity in 2008 and its cisplatin-resistant subline
2008.C13. iNOS expression was examined because NG-
hydroxy-L-arginine and NO produced by the activity of
this enzyme are known inhibitors of arginase activity.
However, the addition of NMMA, an iNOS inhibitor did
not abolish rIFN-γ-induced changes in arginase activity
(Table 2), which is consistent with the RT-PCR data show-
ing an absence of iNOS expression. Analysis of mRNA
transcripts from all 6 EOC cell lines shows that arginase II
was the enzyme responsible for the arginase activity (Fig.
2A). Treatment of the cell cultures with rIFN-γ did not
increase arginase II transcript expression in any of the 6
cell lines tested. IDO, which is constitutively expressed inJournal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/5
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Expression of arginase II (A) and IDO (B) in EOC cell lines Figure 2
Expression of arginase II (A) and IDO (B) in EOC cell lines. The cells were treated with rIFN-γ or left untreated. RNA 
was extracted and RT-PCR performed as described in Materials and Methods. Shown are the results obtained for HEY cells 
treated with rIFN-γ (lane 1), control untreated HEY cells (lane 2), OVCAR3 cells treated with rIFN-γ (lane 3), control 
OVCAR3 cells (lane 4), CAOV3 cells treated with rIFN-γ (lane 5), control CAOV3 cells (lane 6), SKOV3 cells treated with 
IFN-γ (lane 7), control SKOV3 cells (lane 8), 2008.13 treated with rIFN-γ (lane 9), control 2008.C13 cells (lane 10), 2008 cells 
treated with rIFN-γ (lane 11), control 2008 cells (lane 12). M: molecular weight marker.
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the EOC cell lines (Figs. 2A and 2B), was increased by
more than two-fold in 5 of the 6 ovarian cancer cell lines
treated with IFN-γ (Fig. 2B). In contrast to arginase II and
IDO, arginase I and iNOS were not detected in any of
these cell lines when cultured in medium alone or with
rIFN-γ (data not shown).
rIFN-γ produced significant growth inhibition in 7 of 8
cell lines examined, the exception being SKOV3, a cell line
with negligible arginase activity (Table 1). Since the
growth-inhibitory activity of rIFN-γ in certain EOC lines
appeared to be accompanied with arginase inhibition,
and since formation of ornithine from arginine catalyzed
by arginase represents the first step in the synthesis of
polyamines, we hypothesized the inhibition of arginase
activity might be at least partly responsible for the growth-
inhibitory effects of rIFN-γ on EOC cell lines. However,
the addition of polyamines, ornithine, putrescine, or sper-
midine did not abolish the growth-inhibitory activity of
rIFN-γ (Fig. 3). In addition, there was no interference with
growth inhibition by rIFN-γ in EOC cell lines after treat-
ment with NG-hydroxy-L-arginine, an arginase inhibitor.
Conclusions
This study has shown that EOC cell lines have variable lev-
els of arginase activity, which was also observed in cell
lines with elevated levels of the Ki-67 proliferation
marker. Among the cell lines examined, CAOV3 and 2008
are considered platinum-sensitive, SKOV3 and 2774 are
moderately sensitive, and HEY, 2008.C13 and NMP-1 are
platinum-resistant. OVCAR3, the parental line of NMP-1
is also considered platinum-resistant. Elevated arginase
activity was observed in both platinum-sensitive 2008
cells and the platinum-resistant subline, 2008.C13, and it
was substantially higher in NMP-1 cells than in the paren-
tal line, OVCAR3, both platinum-resistant. Although argi-
nase activity was higher in 2008.C13 and NMP-1 cells,
platinum-sensitive cell lines, e.g., CAOV3, exhibited ele-
vated arginase activity, while some platinum-resistant
lines, e.g., HEY, showed reduced arginase activity. It there-
fore appears that there is no direct association between
arginase activity and platinum-resistance. iNOS expres-
sion was not detected in any of the 8 cell lines examined,
even after treatment with rIFN-γ. In contrast, IDO tran-
scripts were expressed by 5 of the 6 EOC lines treated with
Table 1: Arginase activity in EOC cell lines
Cell line Ki67 (%) Arginase II
RT-PCR
Arginase activity
(µg urea/mg protein) – control
Arginase activity
(µg urea/mg protein) – rIFN-γ-treated cells
Cytostasis (%)
2774* 95 + 1.79 0.35 47.2 + 11.9
CAOV3 93 + 1.00 0.51 80.9 + 6.2
NMP-1 84 + 0.36 0.09 83.6 + 6.9
2008* 31 + 0.69 4.90 70.8 + 13.8
2008.C13 34 + 1.00 3.02 54.2 + 15.4
HEY 91 +/- 0.14 0.14 57.8 + 22.6
SKOV3 72 +/- 0.18 0.18 7.5 + 4.1
OVCAR3 54 +/- 0.08 0.09 44.1 + 19.1
The percentage of Ki-67 was determined by immunocytochemistry, and the expression of arginase II was examined by RT-PCR as described in 
Materials and Methods. Arginase activity and growth inhibition were determined after 72 hours of incubation with control medium or rIFN-γ and 
are representative of 4 independent experiments. rIFN-γ was added daily to the cells. *Platinum-sensitive.
Table 2: Effect of NG-methyl-L-arginine on inhibition of arginase activity by rIFN-γ
Cell line Arginase activity (µg urea/mg protein)
Control NMMA (1 mM) rIFN-γ (500 U/ml) rIFN-γ + NMMA
2774 1.8 1.7 1.0 0.7
CAOV3 2.1 1.5 0.8 0.6
NMP-1 0.5 0.5 0.1 0.1
2008 1.2 1.3 2.1 2.4
2008.C13 1.6 1.6 2.6 3.4
The cells were incubated with control medium, rIFN-γ, and/or NMMA for 72 hours and processed as described in Materials and Methods.Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/5
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rIFN-γ. These results showing no iNOS expression differ
from other reported findings in human tumor cell lines,
including EOC [28,30–32]. iNOS has been previously
detected in some EOC lines but was absent in other cell
lines, such as the 2774 cell line [33]. iNOS expression was
detected in AD10, a doxorubicin-resistant subline, but not
in the parental A2780 EOC line [34]. In another study,
iNOS activity was detected after OVCAR3 cells in vitro
were treated with a combination of rIFN-γ, interleukin-1,
and tumor necrosis factor-α [33,35]. In our experiments,
rIFN-γ was not combined with other cytokines, which
may explain the lack of expression of iNOS.
Treatment of the EOC cell lines with rIFN-γ produced dif-
ferent effects on arginase activity, with inhibition of argi-
nase activity in 3 cell lines, 2774, NMP-1, and CAOV3. In
contrast, arginase activity increased after rIFN-γ treatment
of 2008 and 2008.C13 cells. rIFN-γ induces iNOS, and
NG-hydroxy-L-arginine, an intermediate in NO synthesis
by iNOS, is a potent inhibitor of arginase [3,4]. In addi-
tion, NO inhibits ornithine decarboxylase in the Caco-2
colon cancer cell line [36]. However, iNOS was not
detected by RT-PCR after EOC cells were treated with
rIFN-γ, and the addition of NMMA did not abolish the
inhibition of arginase activity by rIFN-γ, making it
unlikely that the simultaneous induction of iNOS could
be responsible for the inhibition of arginase activity in the
cell lines. The mechanism(s) of arginase inhibition by
rIFN-γ have still to be elucidated. From the present data,
regulation of arginase activity by rIFN-γ at the transcrip-
tional level cannot be excluded. There could be different
regulatory effects operating in different cell lines, as
shown by the results of our experiments. Future
experiments could address the mechanism of transcrip-
tional regulation of arginase II by rIFN-γ.
In contrast to the effects of rIFN-γ on arginase II transcript
expression, treatment with rIFN-γ increased or induced
the expression of IDO. This is in agreement with other
reports on the effects of rIFN-γ on various tumor cell lines
[16,17], including EOC [13]. Consistent with an increase
in the expression of IDO, it has been shown that, at least
in some experimental systems, the depletion of L-tryp-
tophan is responsible for the antiproliferative activity of
rIFN-γ, and rIFN-γ-mediated growth inhibition could be
reversed by adding L-tryptophan [16,17]. The depletion of
L-tryptophan is also thought to be responsible for the
growth-inhibitory activity of rIFN-γ in certain in vivo mod-
els [13,14]. However, L-tryptophan depletion is not the
only mechanism responsible for the antiproliferative
activity of rIFN-γ [17]. Metabolites resulting from L-tryp-
tophan catabolism by IDO (e.g. kynurenine, 3-hydroxy-
kynurenine, or picolinic acid), may also exhibit antitumor
activity [29].
In our experiments, the growth-inhibitory activity of rIFN-
γ was sometimes, but not always accompanied by the
inhibition of arginase activity. Formation of ornithine
from L-arginine catalyzed by arginase is the first step in
the synthesis of polyamines. The induction of STAT1 and
p21WAF1/CIP1  mediates growth inhibition by rIFN-γ
[15,37,38], and p21WAF1/CIP1 is involved in growth inhibi-
tion induced by polyamine depletion [8,39,40]. In addi-
tion, the inhibition of arginase activity by NG-hydroxy-L-
arginine causes growth inhibition in breast cancer cell line
MDA-MB-468 [28] and colon adenocarcinoma cell line
Caco-2 [36]. We therefore hypothesized that the inhibi-
tion of arginase activity might represent another mecha-
nism, at least partly, responsible for the growth-inhibitory
effects of rIFN-γ on EOC cell lines.
Cytostatic activity of IFN-γ, NG-hydroxy-L-arginine and the  effect of polyamines on IFN-γ-induced cytostasis Figure 3
Cytostatic activity of IFN-γ, NG-hydroxy-L-arginine 
and the effect of polyamines on IFN-γ-induced cytos-
tasis. NMP-1 cells were seeded at 104 cells/well into 96-well 
plates in RPMI 1640 with 10% fetal calf serum and cultured 
overnight. The next day, the cells were washed with phos-
phate buffered salines, and the medium was replaced with a 
low-arginine, serum-free medium (5% bovine serum albumin, 
1.5% Iscove's modified Dulbecco's medium [GIBCO], 0.2% 
glucose, 0.01% magnesium sulfate, 0.016% calcium chloride, 
transferrin 5.5 µg/ml, and insulin 4 µg/ml in Hank's balanced 
salt medium [GIBCO], pH 7.4) alone or with rIFN-γ (500 U/
ml). The arginine concentration of this medium was 6 µM, 
lower than plasma concentration (normal range, 50–126 µM 
[38]. After another 24 hours, rIFN-γ (500 U/ml), NG-
hydroxy-L-arginine (250 µM), or rIFN-γ plus ornithine (1 
mM), putrescine (1 mM), or spermidine (0.5 mM) was added. 
The cells were then pulsed with [3H] thymidine and incu-
bated for another 24 hours. The cytostatic activity was 
determined as described in Materials and Methods. Similar 
results were observed with other EOC cell lines and when 
experiments were done with RPMI 1640 supplemented with 
10% fetal calf serum. Data shown are representative of 3 sep-
arate experiments.
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Experiments in a medium rich in arginine and at arginine
concentrations significantly lower than physiological lev-
els [41], however, do not support this hypothesis.
Although rIFN-γ treatment results in a decreased transport
of polyamines, supraphysiologic concentrations of
polyamines used in the current experiments would be
expected to compensate for a decrease in the range of 50%
that was reported earlier [42]. In addition, no growth-
inhibition could be induced by NG-hydroxy-L-arginine.
Thus, the decreased production of ornithine induced by
rIFN-γ in tumor cells probably does not result in a
lowering of polyamine concentrations that would affect
the proliferation of the cultured EOC tumor cells. This is
in agreement with the experimental data that demonstrate
that ornithine in tumor-bearing animals is largely pro-
duced in the liver but not in tumor tissues [43]. In addi-
tion, rIFN-γ had significant growth inhibitory effects and
actually increased, rather than decreased, arginase activity
in the 2008 and 2008.C13 cell lines. Arginase I, a cytosolic
enzyme, is expressed mostly in the liver, in contrast to
arginase II, which is located in the mitochondria [44].
This difference in subcellular localization of the two
isoenzymes determines whether ornithine produced by
arginase is more likely to be metabolized by ornithine
decarboxylase (a cytosolic enzyme) to polyamines or by
ornithine aminotransferase (a mitochondrial enzyme) to
pyrroline-5-carboxylate and subsequently to proline or
glutamate. Production of polyamines appears to depend
mostly on arginase I [45–47]. These findings suggest that
arginase II expression by tumor cells may not be as rele-
vant to polyamine synthesis and the regulation of tumor
cell proliferation. In an earlier study, a marked growth
inhibition by NG-hydroxy-L-arginine was observed in a
cell line expressing only arginase I, but not in cell lines
expressing only arginase II [28].
Regulation of alternative pathways of arginine metabo-
lism has been demonstrated by TH1/TH2 cytokines in
monocytes [10,11]. While proinflammatory cytokines
(e.g., rIFN-γ) induce iNOS [9], arginase I is induced by
TH2 cytokines (e.g., interleukin-4) [48]. Little is known
about the effects of cytokines on arginase activity in tumor
cells. Inhibition of arginase activity by rIFN-γ could be of
importance in the tumor microenvironment as utilization
of arginine may be switched to NO synthesis. Arginase has
been shown to have immunosuppressive activity in vitro
[49]. In addition, arginine has been reported to increase
NK cell activity both in vitro and in vivo [50], and a sup-
pression of NK cell activity was observed after arginase
treatment [51]. Inhibition of arginase activity by rIFN-γ
may thus potentiate other effects of this cytokine on the
host immune system. Since rIFN-γ actually increased argi-
nase activity in the 2008 cell line and its cisplatin-resistant
subline, 2008.13, it is possible that rIFN-γ induces a para-
doxical increase in arginase activity in some tumor sys-
tems. This increase in arginase activity in turn might
counterbalance the stimulatory activity of this cytokine on
the cells of the host innate and adaptive immune systems.
In conclusion, arginase expression and activity varied
among EOC cell lines. Arginase activity decreased after
rIFN-γ treatment in 3 of the cell lines and increased in
2008 and 2008.C13 cells. The mechanism of arginase
inhibition is not dependent on NO synthesis. Arginase II
appears to be the isoenzyme responsible for the arginase
activity in EOC cells. The growth-inhibitory effects of
rIFN-γ treatment on EOC cell lines does not appear to be
associated with the inhibition of arginase activity. These
findings, however, do not discount the possibility that ele-
vated arginase activity in EOC cells and its modulation by
rIFN-γ  in vitro might be somehow relevant to the
regulation of the host-tumor interaction in the tumor
microenvironment in vivo.
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